WHO ICTRP trial
Sofosbuvir and Daclatasvir for treatment of Hepatitis-C in patients undergoing…
IRCT20170614034526N3 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT20170614034526N3 |
|---|---|
| Public title | Sofosbuvir and Daclatasvir for treatment of Hepatitis-C in patients undergoing hemodialysis. |
| Scientific title | Efficacy and tolerability of Sofosbuvir and Daclatasvir for treatment of Hepatitis C genotype 3 in patients undergoing hemodialysis- A Prospective interventional clinical trial |
| Primary sponsor | Jinnah Hospital, Lahore |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Countries | Pakistan |
| Conditions | Condition 1: Chronic Viral Hepatitis-C. Condition 2: Chronic kidney disease, stage 5. Chronic viral hepatitis C Chronic kidney disease, stage 5 |
| Interventions | Intervention 1: Intervention group 1: Daclatasvir 60 mg + Sofosbuvir 400 mg once daily for 12 weeks. Intervention 2: Intervention group 2: Daclatasvir 60 mg per day and Sofosbuvir 400 mg 3 times / per week for 12 weeks. |
| Registration date | Mar 8, 2019 |
| Target size | 36 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: